IGCN: Integrative Graph Convolution Networks for patient level insights and biomarker discovery in multi-omics integration

Cagri Ozdemir,Mohammad Al Olaimat,Yashu Vashishath,Serdar Bozdag,Alzheimer's Disease Neuroimaging Initiative
2024-09-24
Abstract:Developing computational tools for integrative analysis across multiple types of omics data has been of immense importance in cancer molecular biology and precision medicine research. While recent advancements have yielded integrative prediction solutions for multi-omics data, these methods lack a comprehensive and cohesive understanding of the rationale behind their specific predictions. To shed light on personalized medicine and unravel previously unknown characteristics within integrative analysis of multi-omics data, we introduce a novel integrative neural network approach for cancer molecular subtype and biomedical classification applications, named Integrative Graph Convolutional Networks (IGCN). IGCN can identify which types of omics receive more emphasis for each patient to predict a certain class. Additionally, IGCN has the capability to pinpoint significant biomarkers from a range of omics data types. To demonstrate the superiority of IGCN, we compare its performance with other state-of-the-art approaches across different cancer subtype and biomedical classification tasks.
Machine Learning
What problem does this paper attempt to address?
The paper aims to address several key issues in multi-omics data integration and proposes a new method—IGCN (Integrative Graph Convolutional Networks) for cancer molecular subtype classification and biomarker discovery. Specifically: 1. **Multi-omics Data Integration**: Current multi-omics data integration methods can predict cancer molecular subtypes but lack a comprehensive understanding of the principles behind specific prediction results. IGCN provides an importance analysis of each type of omics data at the patient level by combining various omics data (such as mRNA expression, DNA methylation, and miRNA expression). 2. **Enhanced Interpretability**: IGCN has interpretability functions that can identify which types of omics data are more important for the specific classification of each patient. Additionally, it can identify important biomarkers from various types of omics data. 3. **Performance Superiority Validation**: To demonstrate the superiority of IGCN, researchers compared it with other existing advanced methods, including performance evaluations on various tasks such as breast cancer, glioblastoma (GBM), and Alzheimer's disease (AD). In summary, this paper aims to improve the accuracy and interpretability of multi-omics data integration through the new IGCN framework, thereby promoting the development of personalized medicine.